CELROSFI
LIVE

Serial Number

97730282

Owner

Turning Point Therapeutics, Inc.

Attorney

Marilyn F. Kelly

Filing Date

Dec 23, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CELROSFI Trademark

Serial Number: 97730282

CELROSFI is a trademark filed by Turning Point Therapeutics, Inc. on December 23, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Turning Point Therapeutics, Inc.

San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

December 23, 2022

Registration Date

Not Registered

Published for Opposition

February 13, 2024

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 25, 2026 EXRA
SOU EXTENSION 4 GRANTED
Mar 24, 2026 EX4G
SOU EXTENSION 4 FILED
Mar 24, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 24, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 25, 2025 EXRA
SOU EXTENSION 3 GRANTED
Sep 24, 2025 EX3G
SOU EXTENSION 3 FILED
Sep 24, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Sep 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 3, 2025 EXRA
SOU EXTENSION 2 GRANTED
Apr 2, 2025 EX2G
SOU EXTENSION 2 FILED
Apr 2, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 2, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 30, 2024 EXRA
SOU EXTENSION 1 GRANTED
Sep 30, 2024 EX1G
SOU EXTENSION 1 FILED
Sep 30, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 30, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 9, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 13, 2024 NPUB
PUBLISHED FOR OPPOSITION
Feb 13, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 8, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 14, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 14, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 26, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 26, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 26, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 23, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 29, 2022 NWOS
NEW APPLICATION ENTERED
Dec 27, 2022 NWAP